FTC paus­es chal­lenge of Am­gen's $28B Hori­zon takeover to con­sid­er set­tle­ment

The FTC is paus­ing its chal­lenge of Am­gen’s pro­posed $28 bil­lion buy­out of Hori­zon Ther­a­peu­tics for sev­er­al weeks to ex­plore al­ter­na­tive ways of re­solv­ing the case, in­clud­ing a pos­si­ble set­tle­ment.

The move, dis­closed in a fil­ing on the FTC’s web­site, marks the lat­est twist in a case that sparked out­cry from drug­mak­ers, claim­ing it would cast a cloud over bio­phar­ma deal­mak­ing. As the FTC takes time to con­sid­er what it calls a “prop­er res­o­lu­tion,” it al­so opens the door to the deal clos­ing with­out a le­gal fight.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER